AAVantgarde Bio, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), published preclinical research in Science Advances demonstrating the safety and efficacy of their dual AAV intein vector gene therapy for Stargardt’s disease in large animal models. This research leverages AAVantgarde’s proprietary AAV intein platform and TIGEM’s expertise in genetic research. The study provides evidence supporting the clinical translation of this promising gene therapy program.
This preclinical success is a crucial step toward addressing the unmet medical need in Stargardt’s disease, an inherited retinal dystrophy that causes progressive vision loss. Positive results in large animal models significantly de-risk the transition to human clinical trials and increase the likelihood of developing an effective treatment. This strengthens AAVantgarde’s position in the competitive ocular gene therapy landscape and offers hope for patients suffering from this debilitating condition.
The study showcases the innovative dual AAV intein vector approach, designed to overcome the limitations of traditional AAV vectors in delivering large genes. The demonstration of both safety and efficacy in large animal models is a key technical achievement, validating the platform’s potential for broader applications beyond Stargardt’s disease and even ocular tissues. This progress may attract further investment and partnerships, accelerating development and potentially expanding the platform’s use in other genetic disorders.
This publication signals significant momentum for AAVantgarde and TIGEM. The positive preclinical data pave the way for clinical trials in humans, potentially leading to the first effective gene therapy for Stargardt’s disease. This advancement also reinforces the potential of the AAV intein platform technology, opening doors for its application in other therapeutic areas and solidifying AAVantgarde’s position as a leader in the gene therapy field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
